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Abstract
A mutant allele of the -chemokine receptor gene CCR5 bearing a 32-basepair (bp) deletion that prevents cell invasion by the
primary transmitting strain of HIV-1 has recently been characterized. Individuals homozygous for the mutation are resistant to
infection, even after repeated high-risk exposure, but this resistance appears not absolute, as isolated cases of HIV-positive deletion
homozygotes are emerging. The consequence of the heterozygous state is not clear, but it may delay the progression to AIDS
in infected individuals. In order to evaluate the frequency distribution of CCR5-32 polymorphism among Egyptians, a total of
200 individuals (154 from Ismailia and 46 from Sinai) were tested. Only two heterozygous individuals from Ismailia carried the
CCR5-32 allele (0.6%), and no homozygous (32/32) individuals were detected among the tested samples. The presence of
the CCR5-32 allele among Egyptians may be attributed to the admixture with people of European descent. Thus we conclude that
the protective deletion CCR5-32 is largely absent in the Egyptian population.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
A mutant allele of the -chemokine receptor gene
CCR5 bearing a 32-basepair (bp) deletion that pre-
vents cell invasion by the primary transmitting strain
of HIV-1 has recently been characterized [1–3]. Indi-
viduals homozygous for the mutation are resistant to
infection, even after repeated high-risk exposure [1,4],
but this resistance appears not absolute, as isolated cases
of HIV-positive deletion homozygotes are emerging [5].
There is little information regarding human immunod-
eficiency virus (HIV) in Egypt. Among IV drug users,
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a high risk group, the prevalence of HIV infection has
already reached 8% in Cairo as of 1994 [6]. HIV infection
levels declined between 1987 and 1993 in Cairo among
male sexually transmitted disease (STD) patients. In
1987–1988, 0.7% were HIV positive; in 1993, 0.3% were
infected. In 1994, there was no evidence of infection
among STD patients attending STD clinics in Alexan-
dria and Assiut [6–9]. The estimated percentage of adults
living with HIV/AIDS in Egypt at the end of 1999 was
0.02% [8].
Chemokine receptors are cell surface proteins that
bind small peptides called chemokines [10]. Chemokines
can be classified into three groups based on the number
and location of conserved cysteines: C, CC, and CXC.
Chemokine receptors are grouped into families on the
basis of the chemokine ligands they bind: CC, CXC,
or both. The chemokine receptor CCR5 is encoded by
0027-5107/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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the CMKBR gene located on the p21.3 region of human
chromosome 3 [11]. The chemokine receptor gene CCR5
has become the object of intense interest since the
discovery of its role in the entry of human immunod-
eficiency virus type 1 (HIV-1) into human CD4-positive
cells [12,13]. The CCR5 gene product is a member of
the seven-transmembrane, G-protein-coupled receptor
family [14,15] which, in response to their normal -
chemokine ligands, is involved in the chemotaxis of
leucocytes towards sites of inflammation [16]. CCR5
also mediates the entry into cells of the M-tropic strain of
HIV-1 that is the primary transmitting form of the virus
[17–21].
Almost simultaneously with the findings of the HIV
coreceptors, a mutation in the gene that encodes CCR5
was reported that confers a high degree of resistance to
HIV infection in vitro and in vivo [1,4]. This mutation,
termed 32, consists in a 32 bp deletion that occurs at a
site of a repeat motif in the CCR5 gene and results in a
frameshift in the coding sequence that produces a non-
functional protein, and as a result it is not expressed in the
cell membrane [22]. It was believed that individuals with
homozygous mutant genotype (32/32) were 100%
resistant to HIV infection, at least with M-tropic strains,
that use the CCR5 molecule as co-receptors. However,
there have been reports of HIV infection in two individu-
als who are homozygous for the mutant allele (32/32)
[5]. These infections could have occurred with T-tropic
strains that use the CXCR4 molecule as coreceptors to
enter the target cells. It has been difficult to establish if the
CCR5/32 genotype confers any degree of resistance
to infection. HIV-infected individuals heterozygous for
CCR5-32 have about a 2-year delay in progression
to AIDS compared with HIV infected individuals who
do not carry the 32 polymorphism [23–25]. Although
the studies on these aspects of disease progression are
contradictory [2,3,23,26].
The global distribution of the CCR5-32 alleles
among diverse human populations is widely variable.
The CCR5-32 allele is more prevalent in Euro-
pean populations and almost absent from Asian groups
[2]. Within European populations a wide variation of
10–20% in CCR5-32 frequency was observed with a
gradient, uppermost at the north around the Baltic Sea
down to the Mediterranean coast. It was inferred that
most, if not all CCR5-32 alleles originate from a sin-
gle mutation event, and that this mutation event probably
took place a few thousand years ago in Northeastern
Europe [11]. The frequency of the mutation is 20.93%
in Ashkenazi Jews [27,28]. In European-derived pop-
ulations from the United States and Southern Europe,
CCR5-32 was observed at a frequency of 5–10%, but
decreased to 2–5% in Hispanic populations, throughout
the Middle East or in the Indian continent. However,
this allele is almost absent among African-Americans
in whom admixture with people of European descent
has been considerable [27]. In Asian populations, the
CCR5-32 alleles were absent among Japanese, Fil-
ipino, Korean, Chinese and Indian populations studied
[29]. In Latin America, the CCR5-32 was not detected
among 32 individuals from Venezuela or in Amerindian
groups [1,27]. The frequency of the allele reaches 5.3%
in Columbia [30].
The age of the CCR5-32 allele has been estimated to
be between 700 and 3500 years old [31,32] with ancient
DNA evidence suggesting an age of 2900 years old [33].
The high frequency of the CCR5-32 allele in some
populations is presumably the consequence of natural
selection possibly driven by an increased resistance to an
infectious agent [34–36]. The geographic spread of the
CCR5-32 resistance allele has recently been studied
to determine how selection and dispersal have interacted
during the history of the allele [37]. In the present study,
the distribution of the CCR5-32 allele among Egyp-
tians and several other diverse human populations was
analyzed.
2. Materials and methods
The human population samples used for this study have
been described previously and were available from previ-
ous studies [38,39]. The samples studied were collected from
unrelated individuals from six populations: Arabic countries
(Egypt and Syria), European (German, Greek and Turk-
ish Cypriots), sub-Saharan Africa (African American) under
institutionally approved internal review board protocols with
informed consent. DNA was prepared from blood leuko-
cytes by standard methods [40]. The genotype determination
was carried out as previously described [24]. The specific
segment of CCR5 gene was amplified by polymerase chain
reaction (PCR) using the following primers [30]: CCR5-
F (5′-ACCAGATCTCAAAAAGAAGGTCT-3′) and CCR5-R
(5′-CATGATGGTGAAGATAAGCCTCACA-3′). PCR ampli-
fication was carried out in 25 l reactions containing 20–100 ng
of template DNA, 40 pM of each oligonucleotide primers,
200 M dNTPs, in 50 mM KCl, 1.5 mM MgCl2, 10 mM
Tris–HCl (pH 8.4) and Taq DNA polymerase (1.25 Units).
The reaction were subjected to 32 cycles: an initial denatu-
ration of 150 s at 94 ◦C, 1 min denaturation at 94 ◦C, 1 min at
the annealing temperature 55 ◦C, extension at 72 ◦C for 1 min.
Following the amplification cycles a final extension was per-
formed at 72 ◦C for 10 min. For analysis, 20 l of each sample
was fractionated on a 3% agarose gel with 0.05 g/ml ethid-
ium bromide. PCR products were directly visualized using
UV fluorescence. For the wild type genotype (CCR5/CCR5),
the PCR product was 225 bp while a product of 193 bp indi-
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Fig. 1. Determination of CCR5 genotypes by agarose gel elec-
trophoresis. DNA fragment patterns of persons with homozygous wild
type (CCR5/CCR5) (lanes 1–4 and 8), homozygous 32 bp deletion
(32/32) (lane 7) or heterozygous genotypes (CCR5/32) (lanes 5
and 6), are shown. Lane 9 is a negative control and lane 10 is 100 bp
marker. The black arrows refer to the fragment size of 225 bp for wild
type and 193 bp for mutant alleles.
cated a homozygous mutant (32/32). The presence of both
fragments indicated a heterozygous genotype (CCR5/32)
(Fig. 1). The allelic and genotypic frequencies were compared
and differences evaluated using the chi square test for good-
ness of fit (χ2). The significant deviation from Hardy–Weinberg
equilibrium (HWE) was evaluated by the same test.
DNA sequencing was performed on gel purified PCR prod-
ucts that had been cloned using the TOPO-TA cloning vector
(Invitrogen) using chain termination sequencing [41] on an
Applied Biosystems 3100 automated DNA sequencer. The
automated DNA sequencing was employed to confirm the
authenticity of the amplified PCR products.
3. Results
The CCR5 genotype was determined by polymerase
chain reaction (PCR) from six diverse population sam-
ples. As shown in Table 1, we found that 152 individuals
from Egypt living in Ismailia were homozygous for the
wild-type CCR5 allele and two were heterozygous for
the CCR5-32 allele, giving a CCR5-32 allelic fre-
quency of 0.006. None of the individuals tested was
homozygous for the mutation (32/32). No mutant
alleles were identified in 46 Egyptian individuals from
the Sinai. Based on the allele frequencies it is possible to
predict the genotype frequency considering that they fol-
low the Hardy–Weinberg equilibrium. This means that
the frequencies have a binomial distribution according
to the following equation: p2 + 2pq + q2 = 1, where p and
q are the allelic frequencies of CCR5 and 32, respec-
tively, and p2, 2pq and q2 are the genotype frequencies of
CCR5/CCR5, CCR5/32, and 32/32, respectively.
No significant deviations from the Hardy–Weinberg
equilibrium were observed. Table 1 shows the frequency
of the CCR5-32 allele in the populations analyzed here
as well as selected populations from previous studies.
The frequency of the CCR5-32 allele was high among
German Europeans (12.8%), moderate in Turkish indi-
viduals from Turkey (6.3%) and from Cyprus (3.2%).
It is found at a very low frequency in Cyprus (Greek)
Table 1
CCR5 genotypes in diverse human populations
Population No. of studied CCR5/CCR5 CCR5/32 32/32
Egypt-Ismailia 154 152 2 0
Egypt-Sinai 46 46 0 0
Syria 69 68 1 0
Lebanon [31] 51 51 0 0
Saudi Arabia [27] 241 231 10 0
Saudi Arabia [31] 100 100 0 0
United Arab Emirates [56] 26 26 0 0
Yemen [27] 34 34 0 0
Sudan [56] 25 25 0 0
Kenya [27] 80 80 0 0
Nigeria [27] 111 110 1 0
African-American 87 85 2 0
German European 74 58 13 3
Turkey [11] 104 91 13 0
Cyprus (Turkish) 47 44 3 0
Cyprus (Greek) 56 55 1 0
Kuwait [42] 393 385 8 0
Syria [42] 106 103 3 0
Jordan [42] 52 52 0 0
Iraq [42] 13 13 0 0
Iran [42] 84 80 4 0
Russia [42] 176 133 43 0
Data from previous studies is denoted by the citations.
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(0.9%) and is completely absent from populations of
African origin except Nigerians and African Americans,
where it is detected at very low frequency. Within the
Arabic populations, the frequency of the mutant 32
allele reached its highest among Saudis 2.07% [27]
and Iranians 2.38% [42]. In a previous study done by
Stephens et al. [31], no mutant alleles were detected
among 100 individuals from Saudi Arabia. By combin-
ing both studies together, the frequency of CCR5-32
among Saudis drops to 1.5%. This frequency is still
higher than any of the other Arabic countries (Table 1).
The frequency of the CCR5-32 was very low among
Syrians (0.7%), Egyptians from Ismailia (0.6%) and
is completely absent from individuals from Lebanon,
Sudan, Yemen, the United Arab Emirates and Egyptians
from the Sinai (Table 1). Our findings suggest that the
CCR5-32 allele is nearly absent from Arabic popu-
lations. However, the near absence of the CCR5 gene
32-bp deletion mutation does not preclude the existence
of other polymorphisms of chemokine receptor genes
associated with slower progression to AIDS within these
populations.
4. Discussion
Despite the apparent resistance afforded by the
CCR5-32 mutation, protection against HIV-1 infection
is not absolute, as evidenced by reports of HIV-1 infec-
tion among 32/32 homozygotes [5,43,44]. Thus far,
however, acquisition of HIV-1 infection in such indi-
viduals has been by the parenteral rather than mucosal
route, suggesting utilization of the CXCR4 coreceptor
by dual-tropic strains of HIV-1 among infected 32
homozygotes. Recently, it was demonstrated that HIV
could use other chemokine receptors such as CCR2 and
CCR3 as coreceptors [45]. Therefore, mutations in these
molecules or in the chemokine receptor ligands might
explain the resistance to HIV infection of some individu-
als. However, the mutation CCR2-64I was not associated
with a resistant phenotype but rather with a delayed in
disease progression [46]. Similarly, the polymorphism
SDF-1-3′ A reported in the -chemokine SDF-1 was
associated with delayed onset of AIDS related symptoms
[47].
The general absence of CCR5-32 in sub-Saharan
Africa suggests a recent origin of the mutation in agree-
ment with a variety of other age estimates [31–33],
but also suggests that it is not a significant factor in
the prevalence or transmission of HIV-1 within Africa.
The high frequency of CCR5-32 in Europe may indi-
cate that it too has had a long term selective advantage
against infectious diseases using CCR5 as entry cofac-
tors, as suggested previously [3,34–36]. Alternatively,
this may be the result of a previously-neutral poly-
morphism whose selective advantage is just becoming
apparent.
The high frequency of the CCR5-32 allele in some
populations could affect the epidemiology of the disease
and the mean progression rate of HIV-positive individu-
als in these populations. It may also favor the emergence
of strains that can bypass the CCR5 defect by using other
coreceptors efficiently [18,20,48]. The uneven distribu-
tion of the genotype across geographic and racial groups
may be related to some previous epidemic, restricted to
Europe that led to a survival advantage among persons
homozygous or heterozygous for the CCR5/32 geno-
type and resulted in a concentration of the CCR5/32
genotype in persons of European ancestry. The bubonic
plague, which claimed the lives of 25–33% of Europeans
during the Black Death from 1346 to 1352 and other large
epidemics such as small pox have been used as exam-
ples to support this [49–53]. Thus, certain populations
appear to have some increase in survival advantage in
the current HIV epidemic. Conversely, populations with
lower frequencies of the CCR5-32 genotype might be
expected to have a higher prevalence of HIV infection
or a more rapid course of the epidemic. A greater risk
for HIV infection has been found among African Amer-
icans than among European Americans from the United
States, when known risk factors, including social class,
were controlled [54]. The prevalence of the CCR5-32
allele is lower in African Americans than in European
Americans. While increasing HIV prevalence in parts of
Asia and Africa may be attributed to social and demo-
graphic factors, as well as differences in the phenotype
of circulating viruses [55], the racial distribution of HIV
risk raises the possibility that differences in the distri-
bution of the CCR5-32 allele or other heritable host
factors/mutations may influence the rate of transmis-
sion or the speed of the epidemic in different racial
groups.
In the Arabic countries, the frequency of the mutant
allele CCR5-32 is very low and probably derived from
admixture with the populations of European descent
rather than as a result of parallel independent mutations.
Future studies are needed to study the chromosomal
haplotypes carrying this mutation and the mutation fre-
quency among the rest of the Arabic populations.
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